Mycotoxins
| Catalog | Product Name / CAS / Description | Structure |
|---|---|---|
| BBF-01949 |
Mniopetal A (158760-98-6) Inquiry |
|
Mniopetal A is a reverse transcriptase inhibitor produced by Mniopetalum sp. 87256. |
||
| BBF-01950 |
Mniopetal B (158760-99-7) Inquiry |
|
Mniopetal B is a reverse transcriptase inhibitor produced by Mniopetalum sp. 87256. |
||
| BBF-01951 |
Mniopetal C (158761-00-3) Inquiry |
|
Mniopetal C is a reverse transcriptase inhibitor produced by Mniopetalum sp. 87256. |
||
| BBF-01952 |
Mniopetal D (158761-01-4) Inquiry |
|
Mniopetal D is a reverse transcriptase inhibitor produced by Mniopetalum sp. 87256. |
||
| BBF-01953 |
Mniopetal E (158761-02-5) Inquiry |
|
Mniopetal E is a reverse transcriptase inhibitor produced by Mniopetalum sp. 87256. |
||
| BBF-01954 |
Mniopetal F (158761-03-6) Inquiry |
|
Mniopetal F is a reverse transcriptase inhibitor produced by Mniopetalum sp. 87256. |
||
| BBF-02488 | ||
SW-163C is an antitumor depsipeptide produced by Streptomyces sp. SNA15896. The LD50 of SW-163C is > 100 mg/kg. |
||
| BBF-02489 | ||
SW-163E is an antitumor depsipeptide produced by Streptomyces sp. SNA15896. The LD50 of SW-163E is 0.6 mg/kg. |
||
| BBF-02499 | ||
TAN-1120 is an anthracycline produced by Streptomyces triangulates subsp. Angiostaticus. It showed remarkably potent angiostatic activity in two conventional angiogenesis assay systems in vivo. |
||
| BBF-02515 | ||
TMC-1A is a Manumycin-associated antibiotic produced by Streptomyces sp. A-230. It has activity against gram-positive bacteria and cytotoxicity to various cancer cells. |
||
| BBF-02516 | ||
TMC-1B is a Manumycin-associated antibiotic produced by Streptomyces sp. A-230. It has activity against gram-positive bacteria and cytotoxicity to various cancer cells. |
||
| BBF-02517 | ||
TMC-1C is a Manumycin-associated antibiotic produced by Streptomyces sp. A-230. It has activity against gram-positive bacteria and cytotoxicity to various cancer cells. |
||
| BBF-02518 | ||
TMC-1D is a Manumycin-associated antibiotic produced by Streptomyces sp. A-230. It has activity against gram-positive bacteria and cytotoxicity to various cancer cells. |
||
| BBF-02529 | ||
TMC-69 is an antitumor antibiotic isolated from the fermentation broth of a fungal strain Chrysosporium sp. TC 1068. It exhibited moderate in vitro cytotoxic activity. |
||
| BBF-02539 | ||
TMC-135A is a triene-ansamycin antibiotic produced by Streptomyces sp. TC 1190. It is cytotoxic to HCT-116, SK-BR-3, HeLa S3, WiDr, HT29 and HL-60 with IC50 values of 0.07, 0.88, 0.11, 0.20, 0.15 and 0.05 μmol/L, respectively. |
||
| BBF-02540 | ||
TMC-135B is a triene-ansamycin antibiotic produced by Streptomyces sp. TC 1190. It is cytotoxic to HCT-116, SK-BR-3, HeLa S3, WiDr, HT29 and HL-60. |
||
| BBF-02541 | ||
TMC-154 is an antibiotic produced by Gliocladium sp. TC 1282. It has cytotoxicity to cancer cells like HCT-1l6, H-60, U937, WiDr. |
||
| BBF-02542 | ||
TMC-169 is an antibiotic of the aspochalasin group produced by Aspergillus flavipes TC 1446. It has cytotoxicity. |
||
| BBF-02543 | ||
TMC-171A is a polyketide antibiotic produced by Gliocladium sp. TC 1304. It has cytotoxicity to cancer cells like HCT-1l6, H-60, U937, WiDr. |
||
| BBF-02544 | ||
TMC-171B is a polyketide antibiotic produced by Gliocladium sp. TC 1304. It has cytotoxicity to cancer cells like HCT-1l6, H-60, U937, WiDr. |
